We have a diversified and balanced clinical development pipeline that covers multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

Compound Mechanism of Action Target Indication Status More information
         
Daridorexant Dual orexin receptor antagonist Insomnia Under review with health authorities

Investor webcast (first study)

Investor webcast (second study)
Aprocitentan*  Dual endothelin receptor antagonist Resistant hypertension management Phase 3 recruitment complete Investor webcast
Clazosentan Endothelin receptor antagonist Cerebral vasospasm assoc.
with aneurysmal subarachnoid hemorrhage
 Japan: NDA submitted
Global: Phase 3		 Investor webcast
Lucerastat Glucosylceramide synthase inhibitor Fabry disease Phase 3 primary endpoint not met
Awaiting interim analysis of OLE**		 Investor webcast
Selatogrel P2Y12 receptor antagonist Suspected acute myocardial infarction Phase 3 Investor webcast
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus Phase 3 in preparation  
ACT-539313 Selective orexin 1 receptor antagonist Binge eating disorder Phase 2   
Sinbaglustat
 GBA2/GCS inhibitor Rare lysosomal storage disorders Phase 1 complete  
ACT-1004-1239 CXCR7 antagonist Immunology  Phase 1  
ACT-1014-6470 - Immunology Phase 1  
ACT-777991 - Immunology Phase 1  


* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide

** Open-label extension study

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 is currently investigated in two Phase 2 studies for the treatment of a rare form of pediatric epilepsy and essential tremor.

 

"I enjoy working for Idorsia because I can be very creative and know that my contribution counts towards building up the business."

Manager, Global Medical Information